HHS IG To Study EPO, OxyContin Reimbursement In 2004 Reports
The HHS' Inspector General plans to study the "appropriateness" of epoetin alfa Medicare reimbursements for patients who have not been diagnosed with end stage renal disease
The HHS' Inspector General plans to study the "appropriateness" of epoetin alfa Medicare reimbursements for patients who have not been diagnosed with end stage renal disease